An m6A-dependent restriction endonuclease, its mutant and its application
Through the MDRE HHPV4I and its mutants extracted from halophilic polymorphic virus, the false positive and false negative problems of m6A detection in the prior art were solved, and high specific cleavage of m6A modification sites in DNA was achieved, improving The accuracy and sensitivity of the detection are suitable for a variety of genetic technology fields.
Patent Information
- Application Number
- CN202210795103.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2022-07-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-07-07
AI Technical Summary
The lack of effective m6A modification-dependent restriction enzymes in the prior art makes it difficult to efficiently detect m6A abundance in eukaryotes, especially in the mammalian genome, and the existing methods are difficult to distinguish. DNA and RNA m6A.
Extracted unique MDRE HHPV4I from Haloarcula hispanicapleomorphic virus 4 as an endonuclease of SRA-wH-HNH type, wild-type and its mutants were developed through gene cloning, expression and purification. ΔSRA, K197A, used to specifically cleave m6A modification sites in DNA.
Achieve high specific cleavage of m6A modification sites in DNA, which can distinguish methylated and non-methylated DNA, improve the accuracy and sensitivity of m6A detection, and is suitable for genetic engineering, gene analysis, gene editing and appearance. Genetics research.
Smart Images

Figure CN116083544B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microbial endonucleases, in particular to an m6A-dependent restriction endonuclease, a mutant thereof and applications thereof. Background Art
[0002] Modification-dependent restriction endonucleases (MDREs) are ubiquitous in prokaryotes and mediate antiviral immunity by targeting phage genomes containing modified bases, such as 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), glucosyl-5-hydroxymethylcytosine (g5hmC), and N6-methyladenine (m6A). To date, many MDREs have been characterized, and these enzymes contain different DNA binding domains and catalytic domains, recognize different modified bases, and show different cleavage properties (Loenen et al., 2014; Lutz et al., 2019; Weigele et al., 2016). Among these identified MDREs, most contain SRA domains that recognize modified cytosine. The SRA domain is characterized as a 5mC-dependent DNA-binding domain in mammals. It is also commonly found in bacteria and is usually fused with a catalytic domain (such as PD-(D / E)XK or HNH) to play a role in DNA cleavage (Unoki et al., 2004; Arita et al., 2004; Han et al., 2015). In recent years, MDREs containing SRA domains have attracted much attention, and a variety of restriction endonucleases containing SRA domains have been characterized, such as SRA-PD-(D / E)XK endonucleases MspJI, AspBHI and LpnPI (Zheng et al., 2010; Cohen-Karni et al., 2011), PD-(D / E)XK-SRA endonucleases PvuRts1I and AbaSI (Wang et al., 2011), and SRA-HNH endonucleases ScoA3IV and TagI (Kisiala et al., 2018). These enzymes all cut DNA at a certain distance from the modified cytosine, but different endonucleases have different specific requirements for the modified bases. For example, MspJI and TagI can cut 5mC and 5hmC modified DNA, but not g5hmC modified DNA; while PvuRts1I can cut 5hmC and g5hmC modified DNA, but not 5mC modified DNA (Kisiala et al., 2018). In addition, the SRA domain belongs to the PUA superfamily, which also contains other DNA or RNA modification binding domains, such as EVE domains and YTH domains (Pastor et al., 2021; Hosford et al., 2020). These domains can also be fused with nucleases, and most fusion proteins function as cytosine modification-dependent endonucleases.
[0003] However, in the prior art, compared with many 5mC modification-dependent restriction endonucleases that have been characterized in detail, few m6A modification-dependent restriction endonucleases have been identified, with only DpnI. The catalytic properties of DpnI are different from those of MDREs containing SRA domains. It recognizes the Gm6ATC site and efficiently cuts fully methylated DNA (Gm6A|TC), leaving a blunt end, while it can also cut hemimethylated DNA to a lesser extent. DpnI consists of an N-terminal PD-(D / E)XK catalytic domain and a C-terminal winged helix (wH) domain, both of which have specific effects on the recognition site Gm6ATC (Lacks et al., 1975; Siwek et al., 2012; Mierzejewska et al., 2014).
[0004] Generally, restriction endonucleases (REases) are widely present in prokaryotes, however, REases have also been found in some chlorella viruses and giant viruses (Xia et al., 1986; Zhang, et al., 1998; Jeudy et al., 2020). Unlike the antiviral function of restriction endonucleases in prokaryotes, enzymes in viruses may help degrade the host genome to recycle deoxynucleotides for the replication of the virus's own DNA, or exclude other viruses in the case of multiple infections (Jeudy et al., 2020; Agarkova et al., 2006). However, to date, MDREs have not been found in viruses.
[0005] m6A is one of the important epigenetic changes in the genomes of vertebrates and plants. It plays a key role in regulating gene expression, chromatin structure control, retrotransposons, stress response, tumorigenesis and early embryonic development (Schübele et al., 2015; Meissner et al., 2013). Currently, there are three main methods for detecting m6A in eukaryotes:
[0006] (1) Mass spectrometry-based detection methods, such as liquid chromatography-mass spectrometry (Huang et al., 2015; Liu et al., 2017), have very high sensitivity, but the influence of microbial contamination must be excluded to avoid false positives. Therefore, ensuring that there is no contamination when preparing samples is key.
[0007] (2) Antibody-dependent detection methods, such as immunoblotting and immunofluorescence, have low sensitivity and are widely used to study m6A. However, since it is impossible to distinguish between DNA m6A and RNA m6A, and the abundance of RNA m6A is usually much higher than that of DNA m6A, it is necessary to remove RNA contamination in DNA for this method. Antibodies can also be used for DIP-seq to detect the distribution of m6A in the genome. m6A DIP-seq will produce a lot of nonspecific signals when the DNA abundance is too low (Douvlatanioti et al., 2020), so this method is not suitable for samples with low abundance.
[0008] (3) Non-antibody-dependent detection methods. The first method is to use methylation-sensitive restriction endonucleases to cut DNA to detect m6A (Luo et al., 2016; Luo et al., 2018). However, methylation-sensitive restriction endonucleases depend on specific DNA sequences (GATC, CATG, etc.), and the existing m6A DIP-seq and SMRT-seq have not detected similar m6A modification sequences in mammalian genomes (Xie et al., 2018; Zhu et al., 2018). Therefore, this type of method is difficult to use for detecting mammalian m6A. Another method is the third-generation sequencing technology. SMRT-seq detects 6mA through changes in the kinetic properties of DNA polymerase during replication (Flusberg et al., 2010), but there are also reports showing that SMRT-seq will produce false positives when the m6A abundance is very low. Therefore, SMRT-seq detection of extremely low-abundance m6A requires enrichment of m6A and very high sequencing coverage. Another highly promising third-generation sequencing technology, nanopore sequencing, has also been reported to be able to detect m6A, but it is currently only used to detect m6A in prokaryotes or unicellular eukaryotes (Rand et al., 2010; McIntyre et al., 2018).
[0009] In summary, it can be concluded that the main methods currently used for DNA methylation detection have various defects. Therefore, it is necessary to develop more novel m6A modification-dependent restriction endonucleases to overcome the above problems. Summary of the invention
[0010] In view of the deficiencies of the above prior art, the present invention provides an m6A-dependent restriction endonuclease, a mutant thereof and an application thereof. In the present invention, a unique MDRE (named HHPV4I) from Haloarcula hispanicapleomorphic virus 4 (HHPV4) is provided for the first time. The HHPV4 virus is the only genome in the family of Lipoviridae that contains an MDRE; its genome is a circular double-stranded DNA with a size of 15010 bp and contains 24 open reading frames (ORFs). The HHPV4I protein is encoded by ORF6 (Atanasova et al., 2018; Demina et al., 2020), but the document only discloses the source of this protein and does not conduct in-depth research on its function. The specific function of the protein encoded by ORF6 was confirmed by the inventors of the present invention and named HHPV4I. The HHPV4I protein consists of an N-terminal SRA domain, a middle wH domain and a C-terminal HNH domain (SRA-wH-HNH type nuclease). The applicant of the present invention has found through gene cloning, expression purification and enzyme property analysis that the catalytic properties of HHPV4I are different from those of DpnI or other characterized nucleases containing SRA domains, and that it is a unique m6A modification-dependent restriction endonuclease. The specific technical contents are as follows.
[0011] An application of an m6A-dependent restriction endonuclease, wherein the m6A-dependent restriction endonuclease is a wild-type m6A-dependent restriction endonuclease HHPV4I (hereinafter referred to as "wild-type HHPV4I"), or a wild-type m6A-dependent restriction endonuclease HHPV4I mutant ΔSRA (hereinafter referred to as "mutant ΔSRA"), or an m6A-dependent restriction endonuclease mutant K197A (hereinafter referred to as "mutant K197A"); the m6A-dependent restriction endonuclease is applied to genetic engineering, gene analysis, gene editing, gene detection, and epigenetic research technology.
[0012] Preferably, in the application of the above-mentioned m6A-dependent restriction endonuclease, the wild-type m6A-dependent restriction endonuclease HHPV4I comprises an N-terminal SRA domain, a middle wH domain and a C-terminal HNH domain, the amino acid sequence of the SRA domain is shown in SEQ ID NO.1, the amino acid sequence of the wH domain is shown in SEQ ID NO.2, and the amino acid sequence of the HNH domain is shown in SEQ ID NO.3;
[0013] The m6A-dependent restriction endonuclease mutant ΔSRA is obtained by a deletion mutation of the SRA domain of the wild-type m6A-dependent restriction endonuclease HHPV4I;
[0014] The m6A-dependent restriction endonuclease mutant K197A is obtained by mutation of the K197 site of the wild-type m6A-dependent restriction endonuclease HHPV4I, specifically, the key amino acid residue K at the K197 site is mutated into A.
[0015] Preferably, the amino acid sequence of the wild-type m6A-dependent restriction endonuclease HHPV4I is shown in SEQ ID NO.4;
[0016] The amino acid sequence of the m6A-dependent restriction endonuclease mutant ΔSRA is shown in SEQ ID NO.5;
[0017] The amino acid sequence of the m6A-dependent restriction endonuclease mutant K197A is shown in SEQ ID NO.6.
[0018] More preferably, the nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.4 is shown as SEQ ID NO.7; the nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.5 is shown as SEQ ID NO.8; and the nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.6 is shown as SEQ ID NO.9.
[0019] Preferably, the m6A-dependent restriction endonuclease can be used to distinguish methylated and non-methylated DNA, detect cleavage sites, and purify DNA that does not contain m6A modification;
[0020] When using the wild-type m6A-dependent restriction endonuclease HHPV4I or the m6A-dependent restriction endonuclease mutant ΔSRA, the methylation site Gm6ATC in the DNA is specifically cut, or the m6A-modified DNA in the DNA sample is digested and removed, or the methylation level of the GATC site in the DNA sample is analyzed;
[0021] The m6A-dependent restriction endonuclease mutant K197A was used to cut all sites containing m6A modifications in DNA.
[0022] It should be noted that the m6A-dependent restriction endonucleases provided by the present invention include wild-type HHPV4I, and two mutants of wild-type HHPV4I, ΔSRA and K197A. These three restriction endonucleases can specifically recognize and cut DNA sequences containing m6A modifications. The difference is that wild-type HHPV4I and mutant ΔSRA can specifically recognize and each contain fragments of Gm6ATC sites, with higher specificity; while mutant K197A can cut various sequences containing m6A modifications. Therefore, in addition to being able to be applied to the above-mentioned fields, as long as it is necessary to use DNA sequences that can recognize and cut m6A modifications, according to the specific differences of the above-mentioned three restriction endonucleases, a suitable realistic endonuclease can be selected for use.
[0023] The present invention also provides an m6A-dependent restriction endonuclease, which contains both the wH domain shown in SEQ ID NO.2 and the HNH domain shown in SEQ ID NO.3;
[0024] Alternatively, it contains the SRA domain shown in SEQ ID NO.1, the wH domain shown in SEQ ID NO.2 with a mutation at the K197 site, and the HNH domain shown in SEQ ID NO.3.
[0025] Preferably, it is the wild-type m6A-dependent restriction endonuclease HHPV4I, or the m6A-dependent restriction endonuclease mutant ΔSRA, or the m6A-dependent restriction endonuclease mutant K197A;
[0026] The amino acid sequence of the wild-type m6A-dependent restriction endonuclease HHPV4I is shown in SEQ ID NO.4;
[0027] The amino acid sequence of the m6A-dependent restriction endonuclease mutant ΔSRA is shown in SEQ ID NO.5;
[0028] The amino acid sequence of the m6A-dependent restriction endonuclease mutant K197A is shown in SEQ ID NO.6.
[0029] The present invention provides the above-mentioned wild-type HHPV4I, which is a SRA-wH-HNH type nuclease, and its catalytic properties are different from DpnI or other characterized nucleases containing SRA domains, and it can specifically recognize the Gm6ATC modification site on the DNA single strand, that is, the GATC site where adenine is methylated and modified, and perform cleavage. The present invention also provides mutants ΔSRA and K197A of the wild-type HHPV4I, and the cleavage of the mutant ΔSRA.
[0030] The present invention also provides a method for purifying the above-mentioned m6A-dependent restriction endonuclease, comprising the following steps:
[0031] S1. Collect the cells cultured after gene induction expression of wild-type m6A-dependent restriction endonuclease HHPV4I, m6A-dependent restriction endonuclease mutant ΔSRA, or m6A-dependent restriction endonuclease mutant K197A, centrifuge at 4°C, 5000 rpm for 10 min, collect the cell pellet, resuspend in lysis buffer and lyse;
[0032] S2. The cell lysate supernatant obtained in step S1 is passed through a Ni-NTA filler pre-equilibrated with a lysis buffer, and then eluted with 10 column volumes of impurity protein elution buffer, and finally eluted the target protein with 5 column volumes of target protein elution buffer.
[0033] During purification, in order to improve the purification efficiency, technicians in this field can also insert a tag protein at the end of the restriction endonuclease, common ones include various histidine tags (for example, the number of histidine His ≥ 6), FLAG tags, HA tags, SBP tags, Avi tags, Nus tags, V5 tags, etc.
[0034] Preferably, in the above purification method, in step S1, the lysis conditions are 4° C. and centrifugation at 12000 rpm for 1 hour.
[0035] Preferably, in the above purification method, the lysis buffer is composed of 20 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole;
[0036] The composition of the impurity protein elution buffer is 20mM Tris-HCl pH 8.0, 300mM NaCl, 50mM imidazole;
[0037] The composition of the protein elution buffer is 20 mM Tris-HCl pH 8.0, 300 mM NaCl, and 200 mM imidazole.
[0038] Compared with the prior art, the present invention is beneficial in that:
[0039] 1. The present invention conducts in-depth research on the unique MDRE (i.e., wild-type m6A-dependent restriction endonuclease HHPV4I) from Haloarcula hispanica pleomorphicvirus 4 (HHPV4), and finds that this HHPV4 protein has the special function of specifically cutting the methylation site Gm6ATC in DNA. This property can be applied to a wide range of genetic technology fields such as genetic engineering, genetic analysis, gene editing, genetic testing, and epigenetic research;
[0040] 2. The present invention conducts in-depth research on the specific cutting function of the wild-type m6A-dependent restriction endonuclease HHPV4I, and finds that the mutant ΔSRA with a deletion in its SRA domain has the same function as the wild-type HHPV4I, and the mutant K197A with a mutation in the K197 site of its wH domain can cut various m6A-modified DNA sequences, so it can also be applied to the corresponding gene technology field;
[0041] 3. The wild-type HHPV4I and its mutants ΔSRA and K197A provided by the present invention have special potential m6A modification site analysis capabilities, providing a direction for the transformation or development of new m6A modification-dependent restriction endonucleases. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 Schematic diagram of the protein structure of the wild-type HHPV4I and its mutants ΔSRA and K197A of the present invention;
[0043] Figure 2 This is a diagram showing the protein purification effect of wild-type HHPV4I, mutants ΔSRA and K197A detected by SDS-PAGE electrophoresis in Example 2;
[0044] Figure 3 This is an agarose gel electrophoresis effect diagram for detecting the cleavage specificity of wild-type HHPV4I in Example 3;
[0045] Figure 4 This is an agarose gel electrophoresis effect diagram of detecting the cleavage activity of wild-type HHPV4I, mutants ΔSRA and K197A in Example 4;
[0046] Figure 5 This is an agarose gel electrophoresis effect diagram for identifying the modified bases recognized by wild-type HHPV4I in Example 5;
[0047] Figure 6 This is a diagram showing the Run-off sequencing results of the cleavage site of the wild-type HHPV4I in Example 6;
[0048] Figure 7 This is a diagram showing the Run-off sequencing results of the cleavage site of the mutant ΔSRA in Example 7;
[0049] Figure 8 This is an agarose gel electrophoresis effect diagram for determining the cleavage mode of wild-type HHPV4I in Example 8;
[0050] Fig. 9 This is an agarose gel electrophoresis effect diagram of the cleavage activity detection of mutant K917A on other m6A modification sites in Example 9. DETAILED DESCRIPTION
[0051] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0052] The wild-type HHPV4I and mutant K197A proteins used in the following examples have amino acid sequences disclosed in SEQ ID NO. 4 and 6. When the mutant ΔSRA protein is prepared by actual expression using the nucleotide sequence, a histidine tag protein is inserted outside the SRA domain at the N-terminus of the amino acid sequence of SEQ ID NO. 4 and SEQ ID NO. 6 for the convenience of purification. The amino acid sequence of the histidine tag protein is shown in SEQ ID NO. 18, and the corresponding nucleotide sequence is shown in SEQ ID NO. 19. At the same time, the stop codon taa is added to the end of the corresponding nucleotide sequence SEQ ID NO. 7 and 9.
[0053] Based on the amino acid sequence disclosed in SEQ ID NO.5 and the corresponding nucleotide sequence SEQID NO.8, when the mutant ΔSRA protein is prepared by actual expression of the nucleotide sequence, in order to facilitate purification, a tag protein and methionine M (codon is atg) are further inserted outside the wH domain at the N-terminus of the amino acid sequence disclosed in SEQ ID NO.5. The amino acid sequence of the histidine tag protein is shown in SEQ ID NO.18, and the corresponding nucleotide sequence is shown in SEQID NO.19. Therefore, the amino acid sequence inserted outside the wH domain at the N-terminus is the histidine tag protein and methionine M, and the corresponding nucleotide sequence is the nucleotide sequence of the histidine tag protein and the codon atg of methionine M. At the same time, a stop codon taa is added to the end of the corresponding nucleotide sequence SEQ ID NO.8.
[0054] Example 1: Study on the structures of HHPV4I, ΔSRA and K197A proteins
[0055] Use IBS tools to draw a schematic diagram of the protein domain, such as Figure 1 As shown in Figure 2, the wild-type HHPV4I consists of three domains, namely the SRA domain at the N-terminus (1-143aa), the wH domain in the middle (144-223aa), and the HNH domain at the C-terminus (224-381aa).
[0056] The mutant ΔSRA indicates that the SRA domain is completely truncated, leaving only the wH and HNH domains; the mutant K197A indicates that the key amino acid residue K in the wH domain is mutated to A.
[0057] Example 2: Cloning of HHPV4I, ΔSRA and K197A genes and protein expression and purification
[0058] 1. Gene cloning of HHPV4, ΔSRA and K197A
[0059] The wild-type HHPV4I gene with a histidine tag was synthesized by Nanjing GenScript Biotechnology Co., Ltd. and ligated into the pQE80L vector with an N-terminal 6×His tag by seamless cloning. The seamless cloning kit was purchased from Shanghai Biotech Biotechnology Co., Ltd. The operation method was strictly followed according to the kit instructions.
[0060] The mutant ΔSRA with a histidine tag and 1 methionine and the mutant K197A with a histidine tag were constructed by the whole plasmid PCR method. The PCR reaction system was 25μl: 2X PrimeSTAR Max 12.5μl (purchased from TaKaRa), 1ng of plasmid template, 0.4μM of forward primer, 0.4μM of reverse primer, and double distilled water to 25μl. The PCR reaction program was: 95℃ pre-denaturation for 5min; 95℃ denaturation for 10s, 58℃ annealing for 10s, 72℃ extension for 1min, 30 cycles; 72℃ final extension for 10min, 16℃ storage for 2min. The amino acid sequences of HHPV4I with a 6×His tag, mutant ΔSRA and K197A are shown in the sequence listing SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6, respectively.
[0061] The nucleotide sequence for expressing the amino acid sequence shown in SEQ ID NO.4 (wild-type HHPV4I gene) is shown in SEQ ID NO.7; the nucleotide sequence for expressing the amino acid sequence shown in SEQ ID NO.5 (mutant ΔSRA) is shown in SEQ ID NO.8; the nucleotide sequence for expressing the amino acid sequence shown in SEQ ID NO.6 (mutant K197A) is shown in SEQ ID NO.9;
[0062] 2. Expression of proteins HHPV4, ΔSRA and K197A
[0063] (1) The obtained recombinant plasmid was transformed into Escherichia coli JM110 competent cells (from Beijing Quanshijin Biotechnology Co., Ltd.). Since Escherichia coli JM110 lacks Dam methylase gene and Dcm methylase gene, the genome of Escherichia coli will not be methylated and will not be degraded by m6A modification-dependent restriction endonuclease. Therefore, wild-type HHPV4I protein can be expressed therein.
[0064] (2) The above bacteria were inoculated into LB medium (1 g yeast extract, 2 g tryptone and 2 g NaCl, all raw materials were purchased from Sinopharm Group) containing 100 mg / mL Amp and cultured in a shaker at 37°C until OD 600 The value was set to 1.0; then the shaking temperature was lowered to 25°C, IPTG (isopropyl-β-D-thiogalactoside) was added at a final concentration of 0.5 mM, and the expression was induced at 25°C, 220 rpm for 5 h.
[0065] The expression process of mutants ΔSRA and K197A was the same as that of wild type.
[0066] 3. Purification of wild-type HHPV4, mutant ΔSRA and mutant K197A
[0067] (1) Bacterial lysis
[0068] The bacterial culture expressing the m6A-dependent restriction endonuclease obtained in the above step was centrifuged at 4°C, 5000rpm for 10min, the supernatant was discarded, and the bacterial precipitate was collected; the bacterial cells were resuspended in lysis buffer (20mM Tris-HCl pH 8.0, 300mMNaCl, 20mM imidazole), the bacterial lysate was placed on ice and the cells were lysed using a pre-cooled ultrasonic disruptor, the cell lysate was centrifuged at 4°C, 12000rpm for 1h, the supernatant was taken and placed on ice.
[0069] (2) Nickel column purification
[0070] The expressed protein has a histidine tag and can be purified using a nickel column. The obtained cell lysate supernatant was passed through a Ni-NTA filler (purchased from Qiagen) pre-equilibrated with lysis buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole);
[0071] Then, 10 column volumes of impurity elution buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 50 mM imidazole) were used to elute the impurity proteins;
[0072] Finally, the target protein was eluted with 5 column volumes of target protein elution buffer (20mM Tris-HCl pH 8.0, 00mM NaCl, 200mM imidazole). The collected target protein was mixed with Coomassie brilliant blue dye or the ultraviolet absorbance at 280nm was detected by ultraviolet analysis instrument to determine whether the protein was purified.
[0073] (3) Protein dialysis
[0074] Cut a 10-15 cm section of dialysis bag, clamp the bottom with a gravity clamp, add the protein into the dialysis bag and seal it with a plastic clip, then put the dialysis bag into a beaker filled with 1L dialysis buffer (50mM Tris-HCl pH 7.5, 100mM NaCl, 0.1mM EDTA, 1mM DTT, 0.1% TritonX-100, 50% glycerol), place the beaker on a magnetic stirrer to stir to promote solution exchange, dialyze in a 4°C chromatography cabinet for 4h, replace with fresh dialysis buffer and dialyze for another 4h, finally collect the dialyzed protein and store it at -20.
[0075] The purification methods of mutants ΔSRA and K197A were the same as those of wild type.
[0076] (4) SDS-PAGE electrophoresis to detect protein purification effect
[0077] After dialysis, the protein concentration was determined, and then the protein size and purity were detected by 10% SDS-PAGE electrophoresis. The sample loading amount was 0.25 mg / mL. The 10% SDS-PAGE gel rapid preparation kit (product number: PG112) was purchased from Shanghai Yazyme Biopharmaceutical Technology Co., Ltd. The gel configuration was strictly carried out according to the kit instructions. The results are shown in Figure 2 shown. Figure 2 The N-terminal of the protein carries a 6×His tag. The size of the wild-type HHPV4 and mutant K197A is about 45 kDa, and the size of the mutant ΔSRA is about 29 kDa. M represents protein marker. Figure 2 It was observed that the purified protein bands were single and of consistent molecular weight, indicating that the proteins obtained after the above purification steps for wild-type HHPV4I, mutant ΔSRA and K197A were of high purity and met the requirements for in vitro biochemical experiments.
[0078] Example 3: Verification of cleavage specificity of wild-type HHPV4I
[0079] 1. Preparation of cleavage substrate
[0080] Plasmid pBR322 (Dam - D -) was extracted from the Escherichia coli JM110 strain lacking the Dam methylase gene and the Dcm methylase gene (purchased from Beijing Quanshijin Biotechnology Co., Ltd.).
[0081] Plasmid pBR322 (Dam + D + ) was extracted from the Escherichia coli DH5α strain carrying the Dam and Dcm methylase genes (purchased from Beijing Quanshijin Biotechnology Co., Ltd.).
[0082] 2. Cutting reaction
[0083] (1) The total volume of the reaction system was 10 mL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 1 mL, DNA substrate 0.4 mg, wild-type HHPV4I concentration gradient, and double distilled water to 10 mL.
[0084] (2) Mix the reaction mixture thoroughly and react at 37°C for 1 h. After the reaction is complete, add 2 mL of 6× DNA Loading Dye to terminate the reaction.
[0085] (3) Finally, the cleavage products were detected by 1% agarose gel electrophoresis and EB staining. Figure 3 As shown, the cleavage activity of wild-type HHPV4I depends on methylation modification. Different concentrations of HHPV4I were used to interact with the unmethylated plasmid pBR322 (Dam - D - ) and methylated plasmid pBR322 (Dam + D + ) were incubated with the result that the wild-type HHPV4I could not effectively cut the non-methylated plasmid, but could specifically cut the methylated plasmid.
[0086] Example 4: Detection of the cleavage activity of wild-type HHPV4I, mutants ΔSRA and K197A
[0087] 1. Preparation of cleavage substrate
[0088] Substrate pBR322 (Dam + D + ) was isolated from Escherichia coli DH5α strain (purchased from Beijing Quanshijin Biotechnology Co., Ltd.).
[0089] 2. Cutting reaction
[0090] (1) The total volume of the reaction system was 10 mL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 1 mL, DNA substrate 0.4 mg, wild-type HHPV4I or mutant ΔSRA or mutant K197A 0.5 mM, and double distilled water was added to 10 mL;
[0091] (2) Mix the reaction mixture thoroughly and react at 37°C for 1 h. After the reaction is complete, add 2 mL of 6× DNA Loading Dye to terminate the reaction.
[0092] (3) The cleavage products were detected by 1% agarose gel electrophoresis (agarose purchased from Shanghai Beijing Biotechnology Co., Ltd.) and stained in 0.5 g / mL EB (EB purchased from Beijing Solebold Technology Co., Ltd.) for 15 min. The results are as follows: Figure 4 As shown, the digestion substrate is methylated pBR322 (Dam + D + ), the results showed that the activity of ΔSRA was not affected and still retained the same strong cleavage activity as the wild-type HHPV4I, while the cleavage activity of K197A was significantly weakened.
[0093] Example 5: Identification of modified bases recognized by wild-type HHPV4I
[0094] 1. Preparation of cleavage substrate
[0095] (1) Plasmid pBR322 (Dam methylase gene) was extracted from the Escherichia coli JM110 strain lacking the Dam methylase gene and the Dcm methylase gene (purchased from Beijing Quanshijin Biotechnology Co., Ltd.). - D - ), and plasmid pBR322 (Dam - D - ) to obtain a 3 kb DNA fragment;
[0096] The amplification primers are shown in the sequence listing as SEQ ID NO.10 and SEQ ID NO.11;
[0097] (2) Methylated by Dam methylase in vitro + ) or Dcm methylase methylation (Dcm + );Dam + Indicates that the GATC site carries m6A modification (Gm6ATC); Dcm + Indicates that the CCWGG site carries 5mC modification (C5mCWGG).
[0098] The Dam or Dcm methylase reaction system is as follows: 1 mg DNA substrate, 1× methyltransferase buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 5 mM 2-mercaptoethanol), 160 μM SAM, 1 mL Dam or Dcm methylase, reaction at 37°C for 1 h; after the reaction, heating at 65°C for 20 min to inactivate the enzyme.
[0099] A PCR purification kit (purchased from Qiagen) was used to purify and recover the DNA methylation product, and the specific purification steps were carried out according to the operating manual.
[0100] 2. Cleavage reaction of wild-type HHPV4I
[0101] (1) HHPV4I was used to cleave unmethylated, Dam methylated, and Dcm methylated 3 kb DNA substrates.
[0102] Restriction endonucleases DpnI and MspJI were used as experimental controls because DpnI can cleave DNA with a Gm6ATC modification site, while MspJI can cleave DNA with a C5mCWGG modification site.
[0103] The total volume of the reaction system was 10 mL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 1 mL, 3 kb DNA substrate 0.4 mg, wild-type HHPV4I 0.5 mM, double distilled water to 10 mL. The reaction mixture was thoroughly mixed and reacted at 37°C for 1 h; after the reaction was completed, 2 mL of 6× DNA Loading Dye was added to terminate the reaction.
[0104] The cleavage reaction steps of DpnI and MspJI in the control group were carried out according to the NEB operation manual, and the amount of cleavage substrate used was the same as that of wild-type HHPV4I. Finally, the cleavage products were detected by 1% agarose gel electrophoresis and EB staining. The results are shown in Figure 5 As shown, wild-type HHPV4I digested unmethylated (non), Dam methylase methylated (Dam + ), Dcm methylase methylation (Dcm + ) 3kb PCR DNA substrate; DpnI (recognizes Gm6ATC) and MspJI (recognizes C5mCWGG) digestion was used as experimental control. The results showed that HHPV4I only cut Dam methylated DNA, but not unmethylated and Dcm methylated DNA, indicating that wild-type HHPV4I is an m6A modification-dependent restriction endonuclease that can recognize the Gm6ATC modification site.
[0105] Example 6: Run-off sequencing method to identify restriction sites
[0106] 1. Cleavage of 600 bp DNA fragment by wild-type HHPV4I
[0107] (1) Substrate preparation
[0108] Plasmid pBR322 (Dam - D - ) to obtain a 600 bp DNA fragment, which contains only one GATC site. The amplification primers are shown in the sequence listing SEQ ID NO.12 and SEQ ID NO.13, and then the 600 bp DNA fragment is methylated by Dam methylase.
[0109] The Dam methylase methylation reaction system is as shown in step 1 of Example 5, namely: 1 mg DNA substrate, 1× methyltransferase buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 5 mM 2-mercaptoethanol), 160 μM SAM, 1 mL Dam or Dcm methylase, react at 37° C. for 1 h; after the reaction, heat at 65° C. for 20 min to inactivate the enzyme.
[0110] (2) Wild-type HHPV4I was used to cut the Dam-methylated 600 bp DNA substrate. The restriction endonuclease DpnI was used as an experimental control. It is known that the cleavage site of DpnI is in the middle of the Gm6ATC modification site. The feasibility of using this method to identify the HHPV4I restriction site can be verified based on the DpnI Run-off sequencing results.
[0111] The cleavage reaction system was 50 mL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 5 mL, 600 bp DNA substrate 1 mg, wild-type HHPV4I 0.25 mM, and double distilled water to 50 mL.
[0112] After mixing the reaction system, place it at 37°C for 15 min, 30 min and 60 min respectively. After the reaction, take out 5 mL of sample into another clean EP tube and add 2 mL of 6×DNA Loading Dye to terminate the reaction;
[0113] Then, the cleavage products at different times were detected by 1% agarose gel electrophoresis (agarose purchased from Shanghai Beijing Biotechnology Co., Ltd.) and stained in 0.5g / mL EB (purchased from Beijing Solebeau Technology Co., Ltd.) for 15 minutes. The results are shown in Figure 6 As shown in Figure A.
[0114] 2. Run-off sequencing
[0115] The remaining 45 mL of the sample was purified and recovered by using a PCR purification kit (purchased from Qiagen), and then the mass concentration of the recovered product was determined by NanoDrop (ThermoFisher Scientific).
[0116] The recovered product was sent to a sequencing company (Beijing Qingke Biotechnology Co., Ltd.) for sequencing. The sequencing primers are shown in the sequence listing as SEQ ID NO.12 and SEQ ID NO.13;
[0117] The peak graph of sequencing results was analyzed using Chromas software. The principle of run-off sequencing is to use the characteristics of Taq DNA polymerase during extension to identify the break site of the template chain. When the template chain breaks, the extension reaction terminates. Due to the terminal nuclease activity of Taq DNA polymerase that is independent of the template, Taq DNA polymerase adds an additional unpaired A to the 3' end of the extended chain. Therefore, when we analyze the peak graph obtained by sequencing, an overlapping double peak (C / A, G / A, T / A) or an enhanced A peak will appear at the template cut, and the subsequent peak will drop sharply, thereby inferring the enzyme's cutting position on the template chain.
[0118] Figure 6 A is the product of enzyme digestion of DNA containing a Gm6ATC site detected by agarose gel electrophoresis. The sample lanes represent no enzyme (-), HHPV4I digestion for 15min, 30min and 60min, and DpnI is used as a control;
[0119] Figure 6 B is the blank control, i.e. the Run-off sequencing result without digestion, with only a single peak in the peak graph;
[0120] Figure 6 C is the Run-off sequencing result of DpnI digestion. After DpnI digestion, an enhanced A peak appears in the peak graph (originally a T peak, but replaced by an A peak) and the subsequent peaks are interrupted, indicating that there is a cut before the T base, thereby inferring the cutting site of DpnI. This result is consistent with the results reported in previous literature, that is, DpnI cuts in the middle of the recognition site Gm6ATC.
[0121] Figure 6 D is the run-off sequencing result of wild-type HHPV4I digestion for 15 minutes. The cleavage site can be observed downstream of the Gm6ATC site on both chains. The peak graphs of forward primer and reverse primer sequencing both show overlapping double peaks, and both are downstream of the Gm6ATC site.
[0122] Figure 6 E is the Run-off sequencing result of wild-type HHPV4I digestion for 30 minutes. Double peaks (i.e., cleavage sites) can be observed downstream or upstream of the Gm6ATC site, indicating that the cleavage is relatively sufficient at this time.
[0123] Figure 6 F is the Run-off sequencing result of wild-type HHPV4I digestion for 60 min. A double peak (cleavage site) was observed only downstream of the Gm6ATC site, indicating that the current DNA was almost completely cleaved.
[0124] The above results indicate that the cleavage sites of wild-type HHPV4I are on both sides of the recognition site Gm6ATC, which has a completely different cleavage mode from DpnI.
[0125] Example 7: Run-off sequencing method to identify the cleavage characteristics of mutant ΔSRA
[0126] The method of this example is basically the same as that of Example 6, except that the enzyme used is mutant ΔSRA. The cleavage product is detected by agarose gel electrophoresis.
[0127] Figure 7 Agarose gel electrophoresis was used to detect the cleavage product of ΔSRA (cleavage substrate and Figure 4 It can be found that the mutant ΔSRA can still specifically cut Dam methylated DNA after the SRA domain is deleted.
[0128] Figure 7 B, 7C, and 7D correspond to the run-off sequencing results of the mutant ΔSRA digesting the DNA substrate for 15 min, 30 min, and 60 min, respectively.
[0129] The results showed that the cleavage site of the mutant ΔSRA was almost exactly the same as that of the wild-type HHPV4I. The lack of the SRA domain did not affect its function, indicating that the SRA domain was not responsible for recognizing the Gm6ATC modification site and cutting DNA. The key to recognizing and cutting the modification site lies in the wH domain and the HNH domain.
[0130] Example 8: Determining the cleavage pattern of wild-type HHPV4I
[0131] 1. Preparation of cleavage substrate
[0132] A 177 bp DNA fragment with a GATC site was amplified from the T7 phage genome by PCR. The amplification primers are shown in the sequence list as SEQ ID NO.14 and SEQ ID NO.15. The PCR reaction system is 25 l: 2X PrimeSTAR Max 12.5 l (purchased from TaKaRa), 1 ng DNA template, 0.4 M forward primer, 0.4 M reverse primer, and double distilled water to 25 l. The PCR reaction program is: 95 ° C pre-denaturation for 5 min; 95 ° C denaturation for 10 s, 72 ° C annealing extension and merging for 2 s, 30 cycles; 72 ° C final extension for 10 min, 16 ° C storage for 2 min; and then methylated in vitro with Dam methylase.
[0133] 2. Cutting reaction
[0134] The total volume of the cleavage reaction system was 10 μL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 1 μL, 177 bp DNA substrate 0.4 μg, wild-type HHPV4I 0.5 μM, and double distilled water to 10 μL.
[0135] The reaction mixture was mixed thoroughly and reacted at 37°C for 15 min, 30 min and 60 min respectively. After the reaction was completed, 2 mL of 6×DNA Loading Dye was added to terminate the reaction. The cleavage products were then detected by 1% agarose gel electrophoresis (agarose purchased from Shanghai Beijing Biotechnology Co., Ltd.) and stained in 0.5 g / mL EB (EB purchased from Beijing Solebold Technology Co., Ltd.) for 15 min. The results are shown in the figure. Figure 8 shown.
[0136] Figure 8 A is the analysis of the cleavage mode of HHPV4I by non-denaturing PAGE gel. HHPV4I was digested for different times, P1 and P4 represent partial cleavage products, P2, P3 and P5 represent final cleavage products. As the digestion time increases, the final cleavage products (P2, P4 and P5) also increase. At 1 hour, a very small fragment (P5) can be clearly seen, that is, the fragment containing the Gm6ATC site. DpnI was used as a control.
[0137] Figure 8 B is a schematic diagram comparing the cleavage modes of HHPV4I and DpnI.
[0138] Example 9: Detection of the cleavage activity of mutant K917A on other m6A modification sites
[0139] 1. Preparation of cleavage substrate
[0140] A 2kb DNA fragment without a GATC site was amplified from the T7 phage genome by PCR, and the amplification primers were shown in the sequence listing SEQ ID NO.16 and SEQ ID NO.17, and then methylated in vitro using M.EcoGII. M.EcoGII methyltransferase is a non-specific methyltransferase that can methylate any adenine residue (N6) in the sequence.
[0141] The total volume of the M.EcoGII methylation reaction system is 50 μL: 1x rCutSmart buffer (50 mM KAc, 20 mM Tris-Ac, 10 mM Mg(Ac)2, 100 μg / mL BSA pH 7.9), 160 μM SAM, 1 μg DNA substrate, 1 μL M.EcoGII, and double distilled water is added to 50 μL.
[0142] The reaction system was mixed and reacted at 37°C for 1 hour. After the reaction, the enzyme was heated at 65°C for 20 minutes to inactivate the enzyme. The DNA methylation product was then purified and recovered using a PCR purification kit (purchased from Qiagen). The specific purification steps were performed according to the operating manual.
[0143] 2. K197A cleavage reaction
[0144] The total volume of the cleavage reaction system was 10 μL: 10× reaction buffer (500 mM Tris-HCl pH 7.9, 1 M NaCl, 50 mM MnCl2) 1 μL, M.EcoGII methylated DNA substrate 0.4 μg, wild-type HHPV4I or mutant K197A 0.5 μM, and double distilled water to 10 μL.
[0145] The reaction mixture was mixed thoroughly and reacted at 37°C for 1 hour. After the reaction was completed, 2 mL of 6×DNA Loading Dye was added to terminate the reaction. The cleavage products were then detected by 1% agarose gel electrophoresis and EB staining. The results were as follows: Fig. 9 shown.
[0146] Fig. 9 In the experiment, the cleavage substrate was DNA without GATC sites methylated by M.EcoGII (M.EcoGII is a non-specific methyltransferase that can methylate any A base); compared with the wild-type HHPV4I, the cleavage efficiency of mutant K197A was much higher, and almost all DNA was cut into small fragments, proving that mutant K197A can cleave various sequences containing m6A modifications.
[0147] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. An application of an m6A-dependent restriction endonuclease, characterized in that: The m6A-dependent restriction endonuclease is a wild-type m6A-dependent restriction endonuclease HHPV4I, or a wild-type m6A-dependent restriction endonuclease HHPV4I mutant ΔSRA, or a m6A-dependent restriction endonuclease mutant K197A; The amino acid sequence of the wild-type m6A-dependent restriction endonuclease HHPV4I is shown in SEQ ID NO.4; The amino acid sequence of the m6A-dependent restriction endonuclease mutant ΔSRA is shown in SEQ ID NO.5; The amino acid sequence of the m6A-dependent restriction endonuclease mutant K197A is shown in SEQ ID NO.6; When using the wild-type m6A-dependent restriction endonuclease HHPV4I or the m6A-dependent restriction endonuclease mutant ΔSRA, the methylation site Gm6ATC in the DNA is specifically cut, or the m6A-modified DNA in the DNA sample is digested and removed, or the methylation level of the GATC site in the DNA sample is analyzed; When the m6A-dependent restriction endonuclease mutant K197A is used, all sites containing m6A modifications in DNA are cut.
2. The use of the m6A-dependent restriction endonuclease according to claim 1, characterized in that The nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.4 is shown in SEQ ID NO.7; the nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.5 is shown in SEQ ID NO.8; the nucleotide sequence used to express the amino acid sequence shown in SEQ ID NO.6 is shown in SEQ ID NO.
9.
3. The use of the m6A-dependent restriction endonuclease according to claim 1 or 2, characterized in that: Used to distinguish methylated and unmethylated DNA, detect cleavage sites, and purify DNA that does not contain m6A modifications.
4. An m6A-dependent restriction endonuclease, characterized in that It is an m6A-dependent restriction endonuclease mutant ΔSRA, or an m6A-dependent restriction endonuclease mutant K197A; the amino acid sequence of the m6A-dependent restriction endonuclease mutant ΔSRA is shown in SEQ ID NO.5; the amino acid sequence of the m6A-dependent restriction endonuclease mutant K197A is shown in SEQ ID NO.
6.
5. A method for purifying the m6A-dependent restriction endonuclease according to claim 4, characterized in that: The following steps are involved: S1. Collect the bacterial cells cultured after gene induction expression of the m6A-dependent restriction endonuclease mutant ΔSRA or the m6A-dependent restriction endonuclease mutant K197A, centrifuge at 4°C, 5000 rpm for 10 min, collect the bacterial precipitate, resuspend it in lysis buffer and lyse it; S2. The cell lysate supernatant obtained in step S1 is passed through a Ni-NTA filler pre-equilibrated with a lysis buffer, and then eluted with 10 column volumes of impurity protein elution buffer, and finally eluted the target protein with 5 column volumes of target protein elution buffer.
6. The purification method according to claim 5, characterized in that In step S1, the lysis conditions are 4°C and centrifugation at 12000 rpm for 1 h.
7. The purification method according to claim 6, characterized in that The lysis buffer consisted of 20 mM Tris-HCl pH 8.0, 300 mM NaCl, and 20 mM imidazole; The composition of the impurity protein elution buffer is 20mM Tris-HCl pH 8.0, 300mM NaCl, 50mM imidazole; The composition of the protein elution buffer is 20 mM Tris-HCl pH 8.0, 300 mM NaCl, and 200 mM imidazole.
